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Tissue factor (TF) is a 47-kd glycoprotein expressed on the cell
surface and a biological initiator of the extrinsic coagulation
pathway as a receptor of factor VII/VIIa (FVII/VIIa) (Nemerson
and Bach, 1982; Morrissey et al, 1987). Under physiological
conditions, TF is expressed only in extravascular cells, including
vascular adventitia, epidermis, mucosal epithelium, and alveolar
macrophages. Some intravascular cells such as vascular endo-
thelium and monocytes express TF when they are stimulated by
several mediators, including bacterial lipopolysaccharides (LPS),
thrombin, CD40 ligand (CD40L), and cytokines (Colucci et al,
1983; Bevilacqua et al, 1984; 1986; Conkling et al, 1988; Drake et
al, 1989; Miller et al, 1998; Slupsky et al, 1998; Zhou et al, 1998).
In cancer tissues, TF expression was reported to be observed in
cancer cells as well as stromal cells by immunohistochemistry
(Zacharski et al, 1983; Wojtukiewicz et al, 1989; Callander et al,
1992).
The coagulation cascade has long been investigated in the role
of cancer progression and metastasis. Inhibition of thrombin by
desulfatohirudin blocked experimental metastasis in mice and
blocking of TF, factor Xa, or thrombin inhibited haematogenous
metastasis in SCID mice (Esumi et al, 1991; Fischer et al, 1995).
These observations emphasized the roles of the coagulation
cascade in cancer metastasis.
Recently, many investigations demonstrated the important roles
of TF function in cancer angiogenesis and metastasis, not only by
its proteolytic activity via the coagulation cascade, but also by its
intracellular signalling. It has been found that TF enhances
vascular endothelial growth factor (VEGF) release (Zhang et al,
1994; Ollivier et al, 1998). In non-small cell lung carcinoma, the
correlation was demonstrated between TF expression and angio-
genic indicators exemplified by microvessel density (MVD) and
VEGF expression, and co-localization of TF and VEGF was
shown in both lung cancer and breast cancer cells (Koomägi and
Volm, 1998; Shoji et al, 1998). TF expression in melanoma cells
induced metastasis independent of the blood coagulation pathway
(Bromberg et al, 1995), and, to the contrary, inhibition of TF func-
tion in human melanoma cells led to reduced haematogenous
metastasis (Mueller et al, 1992). These findings suggest that TF is
deeply involved in tumour progression both as an initiator of the
coagulation pathway and as a mediator of signal transduction.
In the present study, we assessed plasma and tissue TF expres-
sion in breast cancer patients and showed its clinical significance,
especially the prognostic value of TF.
PATIENTS AND METHODS
Patients
Two hundred and thirteen primary breast cancer patients, 24 recur-
rent breast cancer patients, and 18 benign breast disease patients
treated at Tokyo Metropolitan Komagome Hospital from
1983–1996 were enrolled in this study. All patients were female.
All primary cancer patients had no distant metastases. Patients
with liver and renal dysfunction were excluded from this study.
Informed consent was obtained from all. The patients’ age ranged
from 29–85 years, and the average age was 52.3. Clinical stages
were determined according to the criteria of the Japanese Breast
Cancer Society which is based on the Union Internationale Contre
le Cancer (UICC) criteria. All primary patients received either
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mastectomy or partial mastectomy with axillary lymph-node
dissection. Adjuvant treatments were applied according to the
following criteria which did not take account of the TF expression
levels: polychemotherapy was given for 6 months to patients
under the age of 55 with metastasized lymph nodes and hormonal
therapy (tamoxifen) was given to oestrogen receptor (OR)-positive
patients for more than 2 years. In the study, 173 patients received
adjuvant therapy, including 53 chemotherapy, 38 hormonal
therapy, and 82 chemo-endocrine therapy. For all patients, post-
operative physical examinations were performed at least every
3 months. The median follow-up period of surviving patients was
53 months. Liver, lung, brain and distant lymph-node metastases
were diagnosed using computed tomographic scan, and bone
metastasis was diagnosed using X-ray and bone scintigraphy. In
24 recurrent cancer patients, major recurrent sites were found in
liver (n = 4), lung (n = 1), bone (n = 5), and lymph node (n = 14).
All recurrent patients were provided with the following treat-
ments: nine with systemic chemotherapy, four with hormonal
therapy, eight with chemo-endocrine therapy, and three with
surgical resection. Eighteen benign breast disease patients
included nine fibroadenoma, five mastopathy, and four intraductal
papilloma.
ELISA
Using plasma from 24 healthy female controls, 18 benign breast
disease patients, 43 primary and 24 recurrent breast cancer patients
who were treated from 1995–1996, circulating TF concentrations
were examined. Venous blood samples were drawn into sterile
vacuum tubes with 3.2% sodium citrate at the time of the diagnosis
of primary breast cancer or recurrent cancer before treatments.
They were centrifuged at 3000 rpm for 10 min and stored at –20°C
until use. The TF level in the plasma was determined by enzyme-
linked immunosorbent assay (ELISA) (Bobrow et al, 1989;
Nakamura et al, 1993). This ELISA system adopted a sandwich
method using two anti-TF monoclonal antibodies (mAbs)
(HTF-K14, HTF-K180). Ninety six-well plates were coated with
HTF-K14 and blocked with bovine serum albumin (BSA, Fraction
V, Bayer, Germany). After incubation, HTF-K180 conjugated with
horseradish peroxidase (HRP) was added. Then, to amplify the
sensitivity, biotinyl-tyramide (Dupont)/H2O2 was added, followed
by incubation with HRP-conjugated streptavidin (Amersham).
After washing, 2,2¢-azino-bis (3-athylbenz-thiazoline-6-sulfonic
acid) (Boehringer Mannheim Biochemica)/H2O2 was added as a
substrate. The reaction was stopped with 0.01% NaN3 0.1 mol l–1
citric acid and absorbance at 420 nm was measured with the refer-
ence absorbance at 630 nm. Tissue factor was highly purified from
human placenta with an anti-tissue factor antibody (HTF-K14)
column and used as a standard for tissue factor ELISA. Detection
limit of this ELISA was 10 pg ml–1 (Nakamura et al, 1993).
Immunohistochemistry
To assess TF expression, 3–5 mm sections of 213 paraffin-
embedded breast cancer tissues, containing tissues from all
patients whose plasma TF levels were measured, were applied to
indirect anti-peroxidase immunohistochemical assay (Dako, CA,
USA) using an anti-TF mAb (HTF-K108) (Imamura et al, 1993).
After the inhibition of endogenous peroxidase activity, sections
were stained with HTF-K108, followed by reaction with peroxi-
dase-labelled anti-mouse immunoglobulin (Dako, CA, USA).
Peroxidase activity was visualized using 3,3¢-diaminobenzidine
(Nakalai Tesque, Kyoto, Japan) as substrate. After immuno-
staining, the sections were counterstained with haematoxylin
(Muto Pure Chemicals Co, Ltd, Tokyo, Japan).
TF-positive cancer cells (tumour TF) and stromal cells (stromal
TF) were separately counted in the most accumulated five areas in
a  ´ 200 microscopic field. In each of cancer and stroma, the
average of the counts was regarded as TF-positive cell density,
which was classified into three groups: – = < 10%, + = 10–50%,
++ = > 50%. The immunohistochemical and pathological assess-
ment was carried out by two pathologists who had no information
of clinical conditions and plasma TF levels.
Hormone receptor assay
Oestrogen receptor (OR) and progesterone receptor (PgR) were
measured by dextran-coated charcoal (DCC) method using 3H-17
oestradiol or by EIA method. The cut-off values were determined
as 5 fmol mg–1 protein for both hormone receptors.
Statistical analysis
Plasma TF concentration was compared using analysis of variance
(ANOVA) and Fisher’s protected least-significant difference
(PLSD). The chi-square test was carried out for qualitative
analysis. The Spearman’s correlation coefficient by rank was
performed to evaluate the correlation between tissue TF expres-
sion and plasma TF concentration. The survival curves were
drawn by Kaplan–Meier method, and the difference in prognosis
between two groups was analysed by the log-rank test. The
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Figure 1 Plasma TF concentration in normal controls, benign breast
disease patients, and breast cancer patients. Primary and recurrent breast
cancer patients had a significantly higher TF concentration than normal
controls (P = 0.0014 and 0.0114, respectively). There was no difference
between normal controls and benign breast disease patients (P = 0.12) and
between primary and recurrent breast cancer patients (P = 0.71). Among
recurrent sites, no significant difference was observed in plasma TF
concentration (P = 0.68)166 T Ueno et al
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relative risk for each indicator was evaluated by the multivariate
Cox proportional hazards model. P < 0.05 was considered to
indicate statistical significance.
RESULTS
ELISA
The median levels of plasma TF concentration in normal female
controls, benign breast disease, and primary and recurrent breast
cancer patients were 83.85 (25th–75th percentile: 72.40–92.55),
106.1 (94.03–131.3), 111.6 (77.33–155.4), and 120.1
(92.02–145.0) pg ml–1 respectively (Figure 1). Statistical analysis
demonstrated that primary and recurrent breast cancer patients
showed significantly higher plasma TF concentration than normal
controls (P = 0.0014 and 0.0114, respectively), whereas there was
no difference between normal controls and benign breast disease
patients (P = 0.12), and between primary and recurrent breast
cancer patients (P = 0.71). In primary cancer patients, plasma TF
concentration was not significantly associated with any clinical
parameters including clinical stage, tumour size, lymph-node
metastasis, hormone receptor status and pathological findings
(data not shown). In the case of recurrent cancer patients, although
patients with liver metastasis tended to have high plasma TF
concentration, there was no statistical difference among patients
with different recurrent sites (P = 0.68, Figure 1).
Immunohistochemical study
TF expression was observed in tumour cells, fibroblastic cells,
monocytic cells, and vascular endothelial cells (Figure 2). Among
213 primary breast cancer tissues, tumour TF expression was
detected in 193 (90.6%) tissues including 117 + and 76 ++, and
stromal TF expression was detected in almost all tissues (210
tissues, 98.6%) (Figure 2, Table 1). Tumour TF expression closely
correlated with stromal TF expression (P = 0.0005, Table 1). Table
1 shows that both tumour and stromal TF expression were not
associated with any clinical parameters, such as clinical stage,
hormone-receptor status, lymph-node metastasis, and adjuvant
treatments. We assessed the relationship between plasma TF
concentration and TF expression in cancer tissues. Plasma TF
concentration was significantly associated with staining intensity
of TF in cancer tissues. Figure 3 shows that there was a close
correlation between plasma TF levels and TF expression, not only
in tumour cells but also stromal cells (P = 0.0069 and 0.0003,
respectively). Survival analysis revealed that tumour TF-negative
patients (n = 20) had a significantly better prognosis than tumour
TF-positive patients (n = 193) for overall survival (P = 0.041),
although no significant difference was shown for disease-free
survival (P = 0.266) (Figure 4). Moreover, tumour TF expression
was proved to be an independent prognostic indicator for overall
survival by the multivariate analysis (hazard ratio = 4.275, P =
0.0452, Table 2). During the follow-up period, 85 patients under-
went recurrence, and recurrent sites are shown in Table 3. Among
tumour TF-negative patients (mean follow-up period = 84 months,
range = 1–175 months), no metastases in liver, lung, and brain
were observed, whereas 36.7% of tumour TF-positive patients
(mean follow-up period = 58 months, range = 7–173 months)
underwent metastases in those sites.
DISCUSSION
Plasma TF concentration has been reported to be increased in
various disease such as disseminated intravascular coagulation
(DIC), ischaemic heart disease, antiphospholipid syndrome, and
cancer (Koyama et al, 1994; Takahashi et al, 1994; Wada et al,
1994; Kakkar et al, 1995; Suefuji et al, 1997; Cuadrando et al,
1998; Falciani et al, 1998; Misumi et al, 1998). We showed that
plasma TF concentration was up-regulated in primary and recur-
rent breast cancer patients. In glioblastoma cells, shedding of TF
was shown, suggesting that increased concentration of TF in
cancer patients may result from TF emission from tumour cells
as well as stromal cells (Bastida et al, 1994). We demonstrated
that there was a significant correlation between plasma TF
A
C
B
Figure 2 Immunohistochemical studies of TF expression in breast cancer tissues. TF was expressed in both tumour cells and stromal cells, including
fibroblastic cells, monocytic cells, and endothelial cells. (A) tumour TF –, stroma TF ++; (B) tumour TF +, stroma TF +; (C) tumour TF ++, stroma TF ++TF expression in breast cancer 167
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Figure 3 Correlation between TF expression in cancer tissues and plasma TF concentration. Both tumour and stromal TF expression were significantly
associated with plasma TF concentration (P = 0.0069 and 0.0003, respectively).
Table 1 Background analysis
Clinical Tumour TF Stromal TF
parameters – + ++ P –+ + + P
(n = 20) (n = 117) (n = 76) (n = 3) (n = 101)  (n = 109)
Clinical stage
I 4 25 25 2 25 27
II 11 57 37 NS 1 50 54 NS
III 4 27 9 0 19 21
IV 1 5 3 0 5 4
Menopausal status
pre- 9 43 38 1 41 48
post- 11 72 37 NS 2 58 60 NS
Oestrogen receptor (OR)
– 4 38 24 0 26 40
+ 10 56 25 NS 1 43 47 NS
unknown 6 23 27 2 32 22
Progesterone receptor (PgR)
– 5 40 28 1 31 41
+ 9 51 18 NS 0 36 42 NS
unknown 6 24 30 2 33 25
Pathological parameters
Venous invasion (v)
– 0 12 9 1 8 12
1+ 16 71 42 NS 0 57 72 NS
2+ 0 16 1 0 6 11
3+ 0 1 0 0 1 0
Nodal metastasis (n)
– 7 34 24 1 25 39
+ 9 66 28 NS 0 47 56 NS
Adjuvant treatments
hormonal therapy 8 15 15 1 21 16
chemotherapy 5 27 21 NS 0 29 24 NS
chemo-endocrine 5 53 24 1 36 45
none 2 22 16 1 15 24
Stromal TF
–0 2 1
+1 7 6 0 2 4 P = 0.0005
++ 3 55 51
NS, not significant..168 T Ueno et al
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concentration and tissue TF expression in both tumour and stroma,
supporting the view that TF expression in plasma derives from
both tumour cells and stromal cells, including macrophages and
endothelium, in cancer patients. Previously we showed that plasma
TF in female controls was lower than that in male controls
(Nakamura et al, 1993) and, in this study, we used female controls
because all patients were female.
In the immunohistochemical study, we confirmed that TF was
widely expressed in both tumour cells and stromal cells, and that
tumour TF expression was a predictor of poor prognosis in breast
cancer. It was reported that TF expression in tumour cells corre-
lated with grade of malignancy in glioma and pancreatic cancer
(Kakkar et al, 1995; Hamada et al, 1996). In addition, numerous
studies have clarified the role of TF in metastasis and angio-
genesis. In colorectal cancer, TF expression in metastatic liver
tumours increased compared with primary tumours (Shigemori et
al, 1998). Our data showed that tumour TF-positive and -negative
patients differed in the distribution of recurrent sites. In particular,
none of the tumour TF-negative patients had liver metastasis,
although this result is preliminary. Liver metastasis is well-known
to provide a poor prognosis in breast cancer patients (Yamamoto et
al, 1998). Taken together, although no difference in prognosis was
observed for disease-free survival, the difference in metastatic
sites between tumour TF-positive and -negative patients might
result in the significant difference in prognosis for overall survival.
Since the number of tumour TF-negative patients was small,
additional studies are needed to confirm our results. However, our
data imply the importance of TF expression in breast cancer
progression.
Several studies reported that TF was expressed in breast cancer
cells, but the expression varied in degree from 37.5–100% among
investigators (Callander et al, 1992; Contrino et al, 1996; Vrana
et al, 1996). Our study showed that tumour TF-expression was
observed in more than 90% of the breast cancer tissues. Although
this discrepancy may result from differences in the sensitivity of
antibodies, the preparation method of tissues, the condition of
immunohistochemistry, and the criteria of TF-expression levels,
our data coincides with recent studies showing that tumour
TF-expression was observed in almost all breast cancer tissues
(Contrino et al, 1996; Vrana et al, 1996).
Recently, several new findings on the role of tissue factor came
out. The binding of FVIIa to TF induces intracellular calcium ion
oscillation, tyrosine phosphorylation, up-regulation of poly-A
polymerase mRNA and activation of the MAP kinase pathway,
indicating that TF functions not only as a coagulation factor but
also as a mediator of intracellular signaling (Rottingen et al, 1995;
Masuda et al, 1996; Pendurthi et al, 1997; Poulsen et al, 1998). TF
was reported to be associated with the g chain homodimer of the
IgE receptor type I in monocytes (Masuda et al, 1996). In addition,
TF-FVIIa pathway was demonstrated to enhance urokinase
receptor (uPAR) expression in cancer cells, leading to tumour
invasion (Taniguchi et al, 1998). Two-hybrid screening revealed
interaction of TF cytoplasmic domain with actin-binding protein
280 (ABP-280), which mediates cell adhesion and migration (Ott
et al, 1998). These observations suggest that TF might modify the
phenotype of cells into an invasive one by activation of certain
signal transduction pathways. In fact, Chinese hamster ovary
(CHO) cells transfected with TF were reported to acquire
metastatic potential in SCID mice (Mueller and Ruf, 1998). This
phenotypic change may contribute to a poor prognosis in TF-
positive patients.
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Figure 4 (A) Overall survival curve in 213 primary breast cancer patients.
Tumour TF-positive patients had a significantly worse prognosis than tumour
TF-negative patients (P = 0.041). (B) Disease-free survival curve. There was
no significant difference in prognosis between tumour TF-positive and 
-negative patients (P = 0.266).
Table 2 Multivariate analysis for overall survival
Hazard ratio 95% CI P value
Tumour TF: +,++ vs – 4.275 1.031–17.721 0.0452
Oestrogen receptor: – vs + 2.132 1.250– 3.650 0.0055
Lymph node metastasis: + vs – 3.086 1.629– 5.848 0.0005
Tumour size: ³ 2.0 cm vs < 2.0 cm 1.062 0.367– 3.070 0.9116
Table 3 Recurrent sites observed during the follow-up period
Tumour TF Stromal TF
– + ++ – + ++
Liver 0 16 6 0 10 12
Lung 0 10 3 0 3 10
Brain 0 1 2 0 0 3
Bone 3 15 6 0 12 12
Lymph node 3 16 8 0 10 17TF expression in breast cancer 169
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In conclusion, this study demonstrated the association between
the concentration of plasma TF and TF-expression in cancer
tissues, and the significance of tumour TF-expression as an inde-
pendent prognostic indicator for overall survival. It may contribute
to a poor prognosis that TF promotes cancer invasion and metas-
tasis both through activation of the blood coagulation cascade and
through activation of certain intracellular signaling in TF-
expressing cells. A clear identification of the extra- and intracel-
lular function of TF will add greatly to the understanding of the
mechanism of cancer invasion and metastasis.
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